Our observation reinforces the premise that mitigating Aβ effect on Akt activation could constitute a therapeutic approach for GNE myopathy as well as AD or sporadic inclusion body myositis, which are all characterized by intracellular Aβ accumulation. This evidence concerns the gene AKT1 and Alzheimer disease.